AI-Powered Biomedical
Intelligence Platform
Six precision-engineered applications spanning drug safety, molecular visualization, protein simulation, pharmacokinetics, genomics, and clinical research — built to serve Malaysia's healthcare and research sectors.
// Developed in Penang, Malaysia · Powered by EGKAICore — On-Device Edge AI
Drug Safety, Molecular Science
& Protein Simulation
Three flagship AI tools for pharmaceutical research, structural biology, and drug interaction analysis — each powered by EGKAICore, running fully on-device with zero cloud upload, and deployable across iOS, macOS, and Windows.
Detects dangerous drug combinations, classifies severity from minor to life-threatening, and delivers pharmacological explanations — designed for pharmacists, clinical educators, and safety-conscious practitioners.
Visualize proteins in real-time 3D using RCSB Protein Data Bank structures or custom PDB files. EGKAICore predicts binding affinity, free energy calculations, and molecular interactions for pharmaceutical research workflows — entirely on-device.
Integrates SMILES parsing with AI-powered pharmaceutical analysis for researchers, medicinal chemists, and STEM educators — bridging chemical structure to drug-likeness prediction in a single workflow.
Transform RNA-seq data into publication-ready insights. Import DESeq2/edgeR CSVs to generate interactive volcano plots and heatmaps, with pathway enrichment narrated by EGKAICore, on-device.
Professional pharmacokinetic modeling for calculating half-life, clearance, and volume of distribution with AI-assisted dosing simulations. Built for clinical pharmacology and pharmaceutical development workflows.
Real-time tracking of Phase I–IV trials worldwide. AI-summarized outcomes, adverse event classification, and recruitment criteria for researchers and clinicians managing complex trial portfolios.
Unified Biomedical AI Platform
Across Research & Clinical Domains
EGK BioMedic Series is a cohesive AI-powered biomedical ecosystem — spanning drug safety, molecular modeling, protein simulation, genomics, and clinical intelligence.
EGK BioMedic applications are designed for educational and research purposes only. They are not certified medical devices and must not be used for clinical decision-making, patient diagnosis, or treatment planning without validation by qualified healthcare professionals. All AI outputs are computational estimates subject to expert review.
Government & WHO
Collaboration Roadmap
EGK BioMedic Series is proposed as an on-device AI biomedical computation layer — built to support Kementerian Kesihatan Malaysia (KKM) and the World Health Organization across three areas of collaboration.
- Data sandbox access (NOT raw production systems)
- Retrospective anonymised datasets (5–10 years)
- Pilot hospital collaboration (1–2 hospitals initially)
- De-identified clinical outcomes & drug adverse events
- Access to global health datasets
- Participation in pilot digital health programs
- Alignment endorsement with WHO AI guidelines
Access to anonymised, retrospective datasets under a controlled research sandbox, for the purpose of validating EGK's on-device biomedical AI models.
Scope: We are not requesting live patient data or direct EMR access. Engagement begins with historical, de-identified datasets within a sandbox environment, consistent with standard data-governance practice.
- Joint validation studies (UM, UKM, USM clinical researchers)
- Ethics board (IRB) approval support & pathway guidance
- Co-authored publications for mutual academic credibility
- Benchmark datasets for model performance comparison
- AI governance frameworks & ethical AI standards
- Endorsement of specific pilot use cases
- Alignment with WHO Digital Health Strategy 2020–2025
EGK builds and maintains the AI computation layer; clinical partners independently validate the outputs. EGK does not claim clinical authority, and outputs remain subject to expert review.
Note: WHO endorsement, where obtained, would apply to AI governance frameworks and pilot use-case alignment — not to direct validation of any individual EGK product.
- FHIR / HL7 compliance documentation & developer access
- Sandbox API access to hospital system endpoints
- Integration pilot with 1 hospital + 1 insurance provider
- MySejahtera / national health ID interoperability guidance
- Anonymised claims datasets from pilot insurers
- Drug usage patterns for coverage intelligence
- Fraud / anomaly data for detection model training
- Creates a Clinical + Financial AI loop — extremely powerful
Standard FHIR/HL7 integration combined with sandbox access to one hospital and one insurer would let EGK demonstrate a working clinical-financial AI pipeline, end to end, under real interoperability standards.
An On-Device AI Computation Layer, Not a Diagnostic Authority
EGK BioMedic Series is positioned as a secure, on-device AI biomedical computation layer operating within existing regulatory and ethical frameworks — supporting clinical and research decision-making, never replacing the judgment of qualified clinicians.
EGK provides a secure AI biomedical
computation layer that:
• Processes anonymised clinical data
• Enhances decision support
(not replacing doctors)
• Operates within regulatory and
ethical frameworks
• Integrates via standard protocols
(FHIR / HL7)
• PDPA 2010 compliant by design
Introducing EGK AIInsure
AI-Powered Health Insurance
EGK is launching Malaysia's first AI-native health insurance platform — purpose-built to integrate with BioMedic Series clinical data flows. Autonomous claims processing, real-time underwriting, and fraud detection powered by Mushi AI, with full BNM compliance and PDPA 2010 data sovereignty.
The Clinical–Financial AI Loop
EGK AIInsure connects directly to BioMedic Series data outputs — creating a closed-loop AI system spanning clinical intelligence and insurance decisioning.